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Background. Despite recommendations that older adults receive acellular pertussis vaccines, data on direct effectiveness in 
adults aged over 50 years are sparse.
Methods. A case-control study nested within an adult cohort. Cases were identified from linked pertussis notifications and each 
matched to 3 controls on age, sex, and cohort recruitment date. Cases and controls were invited to complete a questionnaire, with 
verification of vaccination status by their primary care provider. Vaccine effectiveness (VE) was estimated by conditional logistic re-
gression, with adjustment for reported contact with children and area of residence.
Results. Of 1112 notified cases in the cohort, we had complete data for 333 cases and 506 controls. Among 172 PCR-diagnosed 
cases (mean age, 61 years), 11.2% versus 19.5% of controls had provider-verified pertussis vaccination, on average, 3.2 years earlier. 
Adjusted VE against PCR-diagnosed pertussis was 52% (95% CI, 15–73%), nonsignificantly higher if vaccinated within 2 years (63%; 
−5–87%). Adjusted VE was similar in adults born before 1950, presumed primed by natural infection (51%; −8–77%) versus those 
born 1950 or later who may have received whole-cell pertussis vaccine (53%; −11–80%) (P-heterogeneity = 0.9). Among 156 cases 
identified by single-point serology, adjusted VE was −55% (−177–13%).
Conclusions. We found modest protection against PCR-confirmed pertussis among older adults (mean age, 61 years; range, 
46–81 years) within 5 years after acellular vaccine. The most likely explanation for the markedly divergent VE estimate from cases 
identified by single-titer serology is misclassification arising from limited diagnostic specificity in our setting.
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Despite widespread vaccination in high-income countries, pertussis 
remains one of the most poorly controlled vaccine-preventable dis-
eases, with outbreaks continuing to occur every few years [1–3]. 
Although severe morbidity is highest in the youngest, adults can 
suffer serious complications [4, 5], with reports suggesting 5–12% 
of those aged over 65 with pertussis are hospitalized [4, 6, 7] and 
about 8% develop radiologically confirmed pneumonia [7].
Formulations of acellular pertussis vaccine suitable for adults 
with reduced amounts of diphtheria and tetanus toxoid (Tdap) 
have been available since 2000. The only randomized controlled 
trial in adults reported vaccine efficacy of 92% (95% confidence 
interval [CI], 32–99%) but was based on 10 cases and excluded 
those aged more than 65 years [8]. More recent studies reported 
satisfactory immunogenicity of Tdap in adults aged more than 
55 [9] and 65 [10] years; however, data on the effectiveness of 
acellular pertussis vaccine in older adults are limited to a single 
case-control study that reported low but imprecise vaccine effec-
tiveness (VE) (24%; 95% CI, −59–64%) in a subgroup of adults 
(mean age, 69 years) [11]. Waning effectiveness of acellular vac-
cine has been demonstrated in children primed with acellular 
vaccines [12], but no data are available for adults primed with 
whole-cell vaccine and/or prior infection.
From 2009 to 2012, the largest Australian state, New South 
Wales (NSW; population 7 million), implemented a cocooning 
vaccination program, which provided free Tdap vaccine to 
adults caring for infants, with vaccine coverage of about 20% in 
a cohort of older adults [13]. We conducted a case-control study 
nested within this cohort, which, based on coverage and ex-
pected numbers of pertussis cases, had 90% power to estimate a 
minimum VE of 40%, with an α = .05. Although recommenda-
tions to vaccinate older adults have been in place for some years 
[3, 14], this study is the first to specifically evaluate the magni-
tude and duration of direct protection in older adults.
METHODS
We used an established cohort, the Sax Institute’s 45 and Up 
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and over residing in NSW were invited from Australia’s national 
health insurance database, the Department of Human Services 
(formerly Medicare Australia) enrollment database, to partic-
ipate. There was oversampling of those living in rural regions 
and those aged more than 80  years. Overall, 267  153 partici-
pants (average age, 62  years) completed a questionnaire and 
consented to be followed up through surveys and linkage to 
health records. The cohort represented 10% of the eligible pop-
ulation in the study age range resident in NSW.
For this nested case-control study, in 2016 the cohort was 
linked to pertussis notifications, hospitalizations, and death 
records by the NSW Centre for Health Record Linkage [16]. 
Pertussis notifications are recorded in the NSW Notifiable 
Conditions Information Management System (NCIMS), which 
is a statutory database of all notifiable conditions required to 
be reported by health practitioners and laboratories under the 
NSW Public Health Act [17]. Cases of pertussis that meet case 
definitions [18] are recorded. Confirmed cases had either defin-
itive laboratory evidence {culture or nucleic acid testing (poly-
merase chain reaction [PCR]) or seroconversion in the absence 
of recent vaccination} or both a clinical history consistent with 
pertussis and suggestive laboratory evidence (single high titer of 
immunoglobulin [Ig] A or IgG antibody to Bordetella pertussis 
or significant change in IgA or IgG, in the absence of vaccination) 
(see Appendix) [18]. Thus, cases notified by laboratories based 
on high single-point serology require active clinical follow-up 
to be considered confirmed, but not if pertussis is detected by 
PCR, which is considered definitive. Data in the NCIMS include 
the notified condition, date of onset, and test type. The NSW 
Admitted Patient Data Collection records all inpatient hospital 
admissions in NSW. For each hospitalization the primary di-
agnosis is coded to the International Classification of Diseases, 
10th revision, Australian Modification (ICD-10-AM) [19]; data 
also include the admission date. Death data are available from 
the NSW Registry of Births, Deaths, and Marriages and include 
the date of death. All databases include identifying details ena-
bling linkage to the 45 and Up Study cohort, and at the time of 
linkage complete data were available until 31 December 2015.
Prior to case and control selection, we excluded cohort par-
ticipants with a linked record of pertussis (either a notification 
or a hospitalization where the primary diagnosis was coded as 
ICD-10-AM A37 Whooping cough) prior to recruitment. We 
also excluded any participants who linked to a death record.
Cases were defined as cohort participants who, following co-
hort recruitment, had a first linked record of pertussis (either 
statutory notification of confirmed pertussis or a hospitaliza-
tion with a primary ICD-10-AM diagnosis code on admission 
of A37 Whooping cough). For each case, up to 3 matched con-
trols were selected from the cohort. Controls were matched 
to cases on age (in 5-year age groups from 45 years), sex, and 
date of cohort recruitment (4 intervals from before 1 July 2007, 
1 July–31 December 2007, 1 January–30 June 2008, after 30 
June 2008)  and assigned an index date equivalent to the per-
tussis onset date for their matched case. We invited all cases and 
matched controls by post and included a questionnaire asking 
about their vaccination status, their contact with children in the 
3 weeks prior to illness or index date, and their healthcare pro-
vider details to verify their vaccination status. We also asked 
cases to provide information about the impact of their per-
tussis diagnosis on their health and work. For those agreeing 
to participate we contacted their healthcare provider to verify 
their pertussis vaccination status. The 45 and Up Study received 
ethics approval from the University of New South Wales’ human 
research ethics committee (HREC) and this specific study re-
ceived approval from the NSW Population and Health Services 
HREC (HREC/10/CIPHS/97). All study participants provided 
written consent to be included.
Statistical Analysis
For our main prespecified analyses, we included only re-
spondent cases and their matched controls, for whom we had 
validated vaccination status from their healthcare provider. 
Participants were classified as vaccinated if they had a health-
care provider–verified pertussis vaccine administered at least 
1 month prior [20] to the pertussis notification or index date 
(for controls). We estimated the odds ratio (OR) of pertussis 
infection using conditional logistic regression and examined 
the effect of adjusting for area of residence, educational level, 
household income, smoking status, asthma, body mass index 
(BMI), attending routine cancer screening, and contact with 
children based on questionnaire responses. Where adjustment 
variables had missing data, in analyses we included those with 
missing data in a separate category. We calculated pertussis VE 
as (1-adjusted OR) × 100%. We estimated VE overall and by 
the pertussis identification method (PCR, serology). For PCR-
confirmed pertussis cases we estimated VE according to time 
since vaccine receipt (<2, 2 to <5, 5+ years compared with no 
vaccination) and by age (<65 vs ≥65 years).
To maximize our analysis population we conducted addi-
tional analyses. For PCR-confirmed cases who had validated 
vaccination records but no respondent matched control with a 
validated vaccination record and who were therefore excluded 
from our main analysis, we selected new matched controls (on 
age group, sex, cohort recruitment date) from the pool of con-
trols with a validated vaccination record but who had no re-
spondent matching case with a validated vaccination record.
All analyses were conducted using R version 3.5.1 [21].
RESULTS
We identified and invited 1112 confirmed cases: 527 (47.4%) 
were based on PCR, 566 (50.9%) on single-titer serology, 
whereas 19 had no laboratory diagnostic information. We in-
vited 3291 corresponding matched controls. Of those invited, 
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agreed to participate, and in participants we obtained validated 
vaccination status for 69% (463 of 671) of cases and 67% (1080 
of 1610) of controls (Figure 1).
Compared with nonparticipating cases, participants were 
more likely to be younger, women, and have higher incomes 
and educational levels and less likely to be current smokers. 
Such differences were less apparent for controls (Table A1). Of 
participants, the proportion of their health practitioners who 
also responded did not vary substantially by a range of char-
acteristics, although practitioner response rates for cases were 
slightly greater for older participants and for never smokers 
(Table A2).
In analyses restricted to cases and their corresponding con-
trols with validated vaccination data (prespecified analysis pop-
ulation), we had 333 cases and 506 controls (Figure 1); 130 cases 
with validated vaccination status lacked a matched control with 
validated vaccination status. The mean age of participants at di-
agnosis/index date was 62 years. Characteristics of the included 
cases and controls were similar except for the proportion re-
porting contact with children in the 3 weeks prior to the onset/
index date (36% of cases vs 23% of controls; see Table 1). In 
analyses confined to the subset of cases with a PCR pertussis di-
agnosis (and their matching controls) we had 172 cases and 266 
controls, with a mean age at diagnosis/index date of 61 years 
(range, 46–81 years). Similar to the prespecified analysis group, 
the only significant difference between cases and controls was 
a higher proportion of cases reporting contact with children 
(Table 2).
In prespecified analyses, the proportions of cases and con-
trols vaccinated were, respectively, 17% (53 of 333) and 16% (82 
of 506); the average time between vaccination and diagnosis/
index date overall was 3.0 years (range, 0.8–8.8 years) and for 
cases and controls, respectively, was 3.0 and 2.9 years. For the 
PCR-only analysis, the proportions of cases and controls vac-
cinated were 12% (20 of 172)  and 20% (52 of 266), respec-
tively, and the mean time since vaccination was 3.2  years. In 
the prespecified population (333 cases, 506 controls) there was 
no evidence of VE (adjusted VE, 8%; 95% CI, −36–37%) (see 
Figure 2). However, VE estimates differed substantially by diag-
nostic method. Among the PCR-only population, adjusted VE 
was 52% (95% CI, 15–73%; P = .01), whereas in the serology-
only population, adjusted VE was −55% (95% CI, −177–13%; 
P  =  .14; P-heterogeneity  =  .005). In addition to matching on 
age, sex, and recruitment date, in the final models the ORs (and 
VE estimates) were adjusted for reported contact with children 
and region of residence. Adjustment for education, income, 
smoking, asthma, BMI, and routine cancer screening did not 
materially change the estimates and were therefore not included 
in the final model.
Among the PCR-only population (N = 438), Figure 3 shows 
VE overall and by time since vaccination and age group. We 
found no trend towards declining VE with greater time since 
vaccination in the PCR-only population, although the cate-
gory “≥5 years since vaccination” had a narrow range (mean, 
5.9 years; range, 5.0–6.7 years). When stratified by age, VE in 
those aged younger than 65 years (mean age, 57.6 years) was sim-
ilar to those aged 65 and over (mean age, 70.0 years) (55% [95% 
CI, 7–78%] vs 49% [95% CI, −32–80%]; P-heterogeneity = 0.8). 
As a post hoc analysis we also estimated VE by birth year 
(<1950/1950+) to correspond to prevaccine and whole-cell per-
tussis vaccine eras [11]. We found no difference in VE: those 
with birth year before 1950 (mean age, 67.5 years; case N = 77) 
had a VE of 51% (95% CI, −8–77%) and those born in 1950 or 
later (mean age, 55.8 years; case N = 85) had a VE of 53% (95% 
CI, −11–80%; P-heterogeneity = 0.9).
There were 61 PCR cases who had no matched controls with 
validated vaccination data and were excluded from the main 
analysis reported in Figure 3. When we included alternate 
Sampling frame: 45 and Up Study cohort 
N=266,951 
Invited participants: based on linked pertussis notification 
or hospitalisation record†, no death record  
Cases N= 1112;  Controls N= 3291 
(PCR cases N=527; serology cases N=566) 
Recruited to study: returned questionnaire and valid consent 
Cases N= 671; Controls N= 1610 
(PCR cases N= 332) 
Participants with doctor validated response: doctor returned 
questionnaire with complete data on vaccination status 
Cases N= 463; Controls N= 1080 
(PCR cases N=233) 
PCR analysis 
population 




Cases N= 333; 
Controls N=506 
†22 cases were idenfied based on a hospitalisaon record with an ICD-10 code A37 indicang 
“Whooping cough”, 3 among those with PCR-noficaon, 10 with serology-noficaon and 9 with no 
noficaon; of these cases with a hospitalisaon record 7 responded (1 PCR, 6 serology, 0 no 
noficaon). Only 3 cases with a hospitalisaon record (all serology) had a doctor validated response 
and at least one matched control and were included in the pre-specified analysis populaon.  
Cases with at least one matched control 
Cases N= 333; Controls N=506 
(PCR cases N= 172) 
PCR analysis with 
rematching  
Cases N= 233; 
Controls N=391 
Figure 1. Study sampling frame, recruitment, and analysis population: flow chart. 
†22 cases were identified based on a hospitalization record with an ICD-10 code 
A37 indicating “Whooping cough”: 3 among those with polymerase chain reaction 
(PCR) notification, 10 with serology notification, and 9 with no notification; of these 
cases with a hospitalization record, 7 responded (1 PCR, 6 serology, 0 no notifica-
tion). Only 3 cases with a hospitalization record (all serology) had a doctor-validated 
response and at least 1 matched control and were included in the prespecified 
analysis population. Abbreviations: ICD-10, International Classification of Diseases, 
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matched controls with validated vaccination data but lacking 
a matched case with validated vaccination data, the number of 
PCR cases increased to 233 with 391 controls. Adjusted VE did 
not change significantly (40%; 95% CI, 4–63%) nor did it differ 
by time since vaccination or by age group (Appendix Figure 1).
For cases notified based on single-point serology and their 
matched controls (N  =  388) we conducted exploratory ana-
lyses to examine if there were differences in VE by time since 
vaccination and whether cases had presumptive evidence of 
active follow-up consistent with them qualifying as truly “con-
firmed” according to case definitions (as follow-up may have 
been incomplete; see “Methods”). We found no differences in 
ORs by time since vaccine receipt, but found that cases with no 
evidence of active follow-up were 5 times more likely to have 
been vaccinated (40.4%; 23 of 57) than those with evidence sug-
gesting follow-up (9.1%; 9 of 99), resulting in substantially dif-
ferent ORs and VE estimates (Table A3).
DISCUSSION
Among older adults (mean age, 61  years), we found signif-
icant effectiveness of acellular pertussis vaccine against PCR-
confirmed pertussis infection of approximately 50%. We did 
not find evidence of waning protection with increasing age 
or with time since vaccination, but these subanalyses lacked 
statistical power.
Our findings add substantially to current evidence on acel-
lular pertussis VE in older adults. The only randomized trial 
estimating efficacy of the adult formulation of acellular pertussis 
vaccine had participants with a mean age of 35 years, excluded 
adults aged over 65, and had limited statistical power [8]. Of 11 
other published studies estimating VE [22–30], all but one [11] 
included only adolescents, most of whom were primed with 
acellular vaccines. The earlier case-control study estimating 
VE in older adults was based on PCR-confirmed cases in a US 
health maintenance organization database. They found, in data 
restricted to cases born in the prevaccine era (before 1950; mean 
age, 69 years; case N = 61), that VE was low and nonsignificant 
(24%; 95% CI, −59–64%), but among those born in the whole-
cell vaccine era (1950–1985; mean age, 43 years; case N = 129) 
VE was substantially higher (68%; 95% CI, 46–82%) [11]. Our 
findings contrast, as we found no significant differences in VE 
by age (<65 vs ≥65 years) nor by equivalent birth cohorts (born 
before 1950 vs 1950 or later).
One major methodological difference between the US study 
and ours is that we had population-based controls while the US 
study had both PCR-negative and population-based controls. 
While the US study found that the use of PCR-negative controls 
resulted in lower VE estimates overall, this difference was only 
observed among the younger subgroup of participants (mean 
age, 11 years), who had all been exposed to acellular vaccines, 
but not in the 2 older subgroups, suggesting this potential for 






Total 333 (100.0) 506 (100.0)  
Recruitment date    
 Before 1 July 2007 64 (19.2) 92 (18.2) .97
 1 July–31 December 2007 20 (6.0) 29 (5.7)  
 1 January–30 June 2008 87 (26.1) 131 (25.9)  
 After 30 June 2008 162 (48.6) 254 (50.2)  
Mean (SD) age at diagnosis/index, years 61.8 (8.0) 61.7 (7.8) .85
Age at diagnosis/index date (years)    
 45–49 18 (5.4) 33 (6.5) .66
 50–54 63 (18.9) 81 (16.0)  
 55–59 63 (18.9) 95 (18.8)  
 60–64 74 (22.2) 134 (26.5)  
 65–69 58 (17.4) 85 (16.8)  
 ≥70 57 (17.1) 78 (15.4)  
Sex    
 Male 106 (31.8) 156 (30.8) .76
 Female 227 (68.2) 350 (69.2)  
Body mass index (kg/m2)    
 <25 103 (30.9) 178 (35.2) .64
 25–30 124 (37.2) 179 (35.4)  
 ≥30 70 (21.0) 100 (19.8)  
 Unknown 36 (10.8) 49 (9.7)  
Highest educational level    
 Certificate or lower 229 (68.8) 326 (64.4) .22
 University or higher 88 (26.4) 161 (31.8)  
 Unknown 16 (4.8) 19 (3.8)  
Residence    
 Major city 150 (45.0) 256 (50.6) .39
 Inner regional 131 (39.3) 174 (34.4)  
 Outer regional or  
remote or very remote
38 (11.4) 59 (11.7)  
 Unknown 14 (4.2) 17 (3.4)  
Annual household income  
(AUD)
   
 <70 000 165 (49.5) 238 (47.0) .77
 ≥70 000 145 (43.5) 230 (45.5)  
 Unknown 23 (6.9) 38 (7.5)  
Smoking status    
 Never 208 (62.5) 304 (60.1) .16
 Past 98 (29.4) 152 (30.0)  
 Current 11 (3.3) 33 (6.5)  
 Unknown 16 (4.8) 17 (3.4)  
Asthma    
 No 264 (79.3) 422 (83.4) .32
 Yes 55 (16.5) 67 (13.2)  
 Unknown 14 (4.2) 17 (3.4)  
Contact with children    
 No 176 (52.9) 246 (48.6) <.001
 Yes 119 (35.7) 115 (22.7)  
 Unknown 38 (11.4) 145 (28.7)  
Attended routine cancer  
screening program
   
 No 38 (11.4) 51 (10.1) .51
 Yes 277 (83.2) 432 (85.4)  
 Unknown 18 (5.4) 23 (4.5)  
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bias may not be uniform across age groups. Differences in VE 
between test-negative and population-based controls are pre-
sumably due to test-negative controls being more similar to the 
cases (ie, having more risk factors leading to pertussis testing 
and subsequent diagnosis than population-based controls). In 
our analyses, to account for differences in the propensity for per-
tussis testing and diagnosis, we adjusted for characteristics in-
cluding contact with children, comorbidities (asthma, smoking, 
BMI), and healthcare seeking (attending cancer screening). 
This adjustment led to an approximately 10% increase in the es-
timated VE rather than any decrease, and was primarily driven 
by adjustment for contact with children. The other factors did 
not materially change our estimates, suggesting that they were 
not major confounders of our results.
None of the earlier reports of VE/efficacy in older adults [8, 
11] attempted to examine waning. Cost-effectiveness analyses 
of vaccination of older adults with acellular pertussis vaccine 
have assumed mean durations of protection of 8  years [31] 
based mostly on studies in children [32], although a much 
shorter duration of protection has been reported among those 
who received all primary doses as acellular vaccine in child-
hood [12]. While we had limited statistical power, we found 
that up to 6 years after vaccination, the point estimate for VE 
showed no declining trend. Based on their age, most adults in 
our study would have been primed, either by having pertussis 
infection or having been vaccinated with whole-cell vaccines as 
a child. Therefore, our findings regarding both the effectiveness 
and duration of protection must be interpreted in this context.
The finding of an association (although not significant) be-
tween pertussis vaccination and a pertussis notification on the 
basis of positive single-titer serology was surprising and incon-
sistent with our results for PCR-confirmed cases. In Australia, 
pertussis notification using single high-titer serology requires 
both clinical evidence and exclusion of recent vaccination (see 
Appendix). Potential flaws in this case reporting include, first, 
variations in the sensitivity and specificity of serological tests 
used by referring laboratories and, second, that public health 
unit workload may preclude active follow-up of notifications 
made directly from laboratories, which account for most per-
tussis notifications in NSW [33]. Our post hoc analyses com-
paring serology cases with and without proxy evidence of 
active follow-up (Table A3) support the likelihood of substan-
tial misclassification among cases identified solely through 
serologic diagnosis. These findings have implications for per-
tussis surveillance in Australia, particularly in adults, a popu-
lation for whom, historically, the majority of notifications were 
based on serological confirmation [2]. Indeed, as more adults 
are vaccinated as part of population-wide programs targeting 
pregnant women or older adults [13], diagnoses based prima-
rily on pertussis serology may become more unreliable and 






Total 172 (39.3) 266 (60.7)  
Recruitment date    
 Before 1 July 2007 24 (14.0) 36 (13.5) .99
 1 July–31 December 2007 13 (7.6) 21 (7.9)  
 1 January–30 June 2008 44 (25.6) 67 (25.2)  
 After 30 June 2008 91 (52.9) 142 (53.4)  
Mean (SD) age at diagnosis/index, years 61.1 ( 7.7) 61.3 ( 7.4) .75
Age at diagnosis/index date (years)    
 45–49 11 (6.4) 19 (7.1) .35
 50–54 37 (21.5) 43 (16.2)  
 55–59 31 (18.0) 45 (16.9)  
 60–64 40 (23.3) 83 (31.2)  
 65–69 29 (16.9) 49 (18.4)  
 ≥70 24 (14.0) 27 (10.2)  
Sex    
 Male 54 (31.4) 83 (31.2) .97
 Female 118 (68.6) 183 (68.8)  
Body mass index (kg/m2)    
 <25 60 (34.9) 97 (36.5) .58
 25–30 66 (38.4) 87 (32.7)  
 ≥30 29 (16.9) 56 (21.1)  
 Unknown 17 (9.9) 26 (9.8)  
Highest educational level    
 Certificate or lower 111 (64.5) 171 (64.3) .96
 University or higher 56 (32.6) 86 (32.3)  
 Unknown 5 (2.9) 9 (3.4)  
Residence    
 Major city 88 (51.2) 121 (45.5) .11
 Inner regional 69 (40.1) 102 (38.3)  
 Outer regional or remote  
or very remote
11 (6.4) 36 (13.5)  
 Unknown 4 (2.3) 7 (2.6)  
Annual household income (AUD)    
 <70 000 74 (43.0) 129 (48.5) .44
 ≥70 000 89 (51.7) 121 (45.5)  
 Unknown 9 (5.2) 16 (6.0)  
Smoking status    
 Never 106 (61.6) 157 (59.0) .19
 Past 58 (33.7) 86 (32.3)  
 Current 3 (1.7) 16 (6.0)  
 Unknown 5 (2.9) 7 (2.6)  
Asthma    
 No 144 (83.7) 222 (83.5) .99
 Yes 24 (14.0) 37 (13.9)  
 Unknown 4 (2.3) 7 (2.6)  
Contact with children    
 No 92 (53.5) 124 (46.6) <.001
 Yes 63 (36.6) 67 (25.2)  
 Unknown 17 ( 9.9) 75 (28.2)  
Attended cancer screening program    
 No 20 (11.6) 22 (8.3) .24
 Yes 146 (84.9) 235 (88.3)  
 Unknown 6 (3.5) 9 (3.4)  
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routine surveillance systems will need to adapt to maintain case 
specificity.
Our study strengths include the relatively large sample size 
and nested matched design, which allowed us to select controls 
who were similar to cases in terms of not only age and sex but 
also characteristics such as health-seeking behavior, which has 
been shown to be higher overall in this cohort than in the ge-
neral population [15]. We were also able to adjust our analyses 
for underlying factors that may be associated with pertussis in-
cidence and severity [4, 6], as well as characteristics associated 
with greater likelihood to participate in the study. Limitations 
include that our response rate was less than anticipated, which 
meant that we had insufficient statistical power for robust VE 
estimates in subgroups including in those aged 65  years and 
older and according to time since vaccination. Also, response 
rates differed by case and control status and may bias our VE 
estimates away from the null if responding controls were more 
likely to be vaccinated, although this was not the case in the 
main prespecified analysis population (see Figure 2). As men-
tioned, we also lacked PCR-negative controls, with the majority 
of the controls’ health practitioners responding that they had 
not been tested for pertussis. Finally, we lacked data on patient 
symptoms, which would have assisted in interpretation of the 
findings based on serological diagnoses.
Overall, we found in adults aged, on average, 61 years that 
acellular pertussis vaccine is approximately 50% effective in 
preventing PCR-confirmed pertussis infection. Together with 
findings from other studies [8, 11], we conclude that while 
Figure 2. Odds ratios and vaccine effectiveness of acellular pertussis vaccine, prespecified population (N = 839). Abbreviations: CI, confidence interval; OR, odds ratio; PCR, 
polymerase chain reaction; Ref, reference.
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effectiveness of the adult acellular pertussis vaccine may decline 
in older age, it still confers a level of protection that is compa-
rable to that often reported for vaccines such as influenza [34], 
which are routinely recommended for older adults. While a 
more effective vaccine would be ideal, Tdap should still be con-
sidered an important intervention among public health strat-
egies to prevent infectious respiratory morbidity in older adults.
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APPENDIX: NATIONAL NOTIFIABLE DISEASES CASE 
DEFINITION FOR PERTUSSIS REPORTING
Both confirmed cases and probable cases should be notified.
Confirmed case: A confirmed case requires either laboratory 
definitive evidence OR laboratory suggestive evidence AND 
clinical evidence.
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Laboratory definitive evidence: Isolation of Bordetella per-
tussis OR detection of B. pertussis by nucleic acid testing OR 
seroconversion in paired sera for B. pertussis using whole-cell 
or specific B. pertussis antigen(s) in the absence of recent per-
tussis vaccination.
Laboratory suggestive evidence: In the absence of recent vac-
cination, significant change (increase or decrease) in antibody 
level (IgG, IgA) to B.  pertussis whole-cell or B.  pertussis–
specific antigen(s) OR single high IgG and/or IgA titer to 
pertussis toxin (PT) OR single high IgA titer to whole-cell 
B. pertussis antigen.
Clinical evidence: A coughing illness lasting 2 or more weeks 
OR paroxysms of coughing OR inspiratory whoop OR post-
tussive vomiting.
Epidemiological evidence: An epidemiological link is es-
tablished when there is contact between 2 people involving 
a plausible mode of transmission at a time when one of 
them is likely to be infectious (from the catarrhal stage, 
approximately 1 week before, to 3 weeks after onset of 
cough) AND the other has an illness that starts within 6 to 
20 days after this contact AND at least 1 case in the chain 
of epidemiologically linked cases (which may involve many 
cases) is a confirmed case with either laboratory definitive 
or laboratory suggestive evidence.
Appendix Figure A1. Odds ratios and vaccine effectiveness of acellular pertussis vaccine: PCR-only population, new matched controls 
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Table A1. Number and Percentage of Participants Responding Overall and According to Case and Control Status
Cases, n/N (% Responded) Controls, n/N (% Responded) Total, n/N (% Responded)
Total 671/1112 (60.3) 1610/3291 (48.9) 2281/4403 (51.8)
Age at diagnosis/index date (years)   
 45–64 441/663 (66.5) 1056/1984 (53.2) 1497/2647 (56.6)
 ≥65 230/449 (51.2) 554/1307 (42.4) 784/1756 (44.6)
Sex    
 Male 215/395 (54.4) 546/1184 (46.1) 761/1579 (48.2)
 Female 456/717 (63.6) 1064/2107 (50.5) 1520/2824 (53.8)
Residence    
 Major city 280/503 (55.7) 797/1698 (46.9) 1077/2201 (48.9)
 Regional or remote 365/576 (63.4) 778/1534 (50.7) 1143/2110 (54.2)
 Unknown 26/33 (78.8) 35/59 (59.3) 61/92 (66.3)
Annual household income (AUD)    
 <70 000 339/596 (56.9) 825/1730 (47.7) 1164/2326 (50.0)
 ≥70 000 311/465 (66.9) 734/1413 (51.9) 1045/1878 (55.6)
 Unknown 21/51 (41.2) 51/148 (34.5) 72/199 (36.2)
Highest educational level    
 No university 477/815 (58.5) 1124/2436 (46.1) 1601/3251 (49.2)
 University 186/278 (66.9) 474/821 (57.7) 660/1099 (60.1)
 Unknown 8/19 (42.1) 12/34 (35.3) 20/53 (37.7)
Smoking status    
 Never 417/665 (62.7) 968/1931 (50.1) 1385/2596 (53.4)
 Past 220/380 (57.9) 543/1107 (49.1) 763/1487 (51.3)
 Current 34/67 (50.7) 98/252 (38.9) 132/319 (41.4)
 Unknown  1/1 (100.0) 1/1 (100.0)
Attended cancer screening program    
 No 73/121 (60.3) 174/410 (42.4) 247/531 (46.5)
 Yes 560/933 (60.0) 1381/2763 (50.0) 1941/3696 (52.5)
 Unknown 38/58 (65.5) 55/118 (46.6) 93/176 (52.8)
Case diagnosis method    
 PCR 332/528 (62.9) … …
 Serology 330/565 (58.4) … …
 Unknown 9/19 (47.4) … …
Diagnosis year    
 <2009 96/167 (57.5) … …
 2009 135/226 (59.7) … …
 2010 89/153 (58.2) … …
 2011 107/180 (59.4) … …
 2012 66/110 (60.0) … …
 2013 41/61 (67.2) … …
 2014 48/71 (67.6) … …
 2015 89/135 (65.9) … …
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Table A2. Number and Percentage of Responding Participants With Validated Vaccination Data From Their Health Care Provider Overall and According 
to Case and Control Status
Cases, n/N (% Responded) Controls, n/N (% Responded) Total, n/N (% Responded)
Total 463/671 (69.0) 1080/1610 (67.1) 1543/2281 (67.6)
Age at diagnosis/index date (years)    
 45–64 294/441 (66.7) 707/1056 (67) 1001/1497 (66.9)
 ≥65 169/230 (73.5) 373/554 (67.3) 542/784 (69.1)
Sex    
 Male 148/215 (68.8) 348/546 (63.7) 496/761 (65.2)
 Female 315/456 (69.1) 732/1064 (68.8) 1047/1520 (68.9)
Residence    
 Major city 201/280 (71.8) 525/797 (65.9) 726/1077 (67.4)
 Regional or remote 243/365 (66.6) 530/778 (68.1) 773/1143 (67.6)
 Unknown 19/26 (73.1) 25/35 (71.4) 44/61 (72.1)
Annual household income (AUD)    
 <70 000 236/339 (69.6) 545/825 (66.1) 781/1164 (67.1)
 ≥70 000 215/311 (69.1) 497/734 (67.7) 712/1045 (68.1)
 Unknown 12/21 (57.1) 38/51 (74.5) 50/72 (69.4)
Highest educational level    
 No university 329/477 (69.0) 736/1124 (65.5) 1065/1601 (66.5)
 University 130/186 (69.9) 337/474 (71.1) 467/660 (70.8)
 Unknown 4/8 (50.0) 7/12 (58.3) 11/20 (55.0)
Smoking status    
 Never 305/417 (73.1) 665/968 (68.7) 970/1385 (70.0)
 Past 144/220 (65.5) 349/543 (64.3) 493/763 (64.6)
 Current 14/34 (41.2) 65/98 (66.3) 79/132 (59.8)
 Unknown  1/1 (100.0) 1/1 (100.0)
Attended cancer screening program    
 No 53/73 (72.6) 103/174 (59.2) 156/247 (63.2)
 Yes 385/560 (68.8) 940/1381 (68.1) 1325/1941 (68.3)
 Unknown 25/38 (65.8) 37/55 (67.3) 62/93 (66.7)
Case diagnosis method    
 PCR 233/332 (70.2) … …
 Serology 223/330 (67.6) … …
 Unknown 7/9 (77.8) … …
Diagnosis year    
 <2009 69/96 (71.9) … …
 2009 83/135 (61.5) … …
 2010 64/89 (71.9) … …
 2011 78/107 (72.9) … …
 2012 46/66 (69.7) … …
 2013 30/41 (73.2) … …
 2014 30/48 (62.5) … …
 2015 63/89 (70.8) … …
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Table A3.  Odds Ratios and Vaccine Effectiveness of Acellular Pertussis Vaccine, Serology-only Population (N = 388) Overall, by Time Since Vaccination, 
and According to Whether There Was a Record of Active Follow-up
Cases Controlsa Unadjusted OR Adjusted ORb Adjusted VE, % (95% CI) P
Serology subgroup       
 Unvaccinated 124 202 Ref Ref Ref  
 Vaccinated 32 30 1.74 1.55 −55 (−177–13) .14
By time since vaccination       
 Unvaccinated 124 202 Ref Ref Ref  
 Vaccinated ≤1 year prior 6 9 1.09 1.27 −27 (−281–60) .68
 Vaccinated >1 year prior 26 21 2.02 1.72 −72 (−241–12) .11
Follow-up record       
 Unvaccinated 90 132 Ref Ref Ref  
 Vaccinated 9 13 1.02 0.83 17 (−128–69) .72
No follow-up record       
 Unvaccinated 34 70 Ref Ref Ref  
 Vaccinated 23 17 2.79 2.57 −157 (−464 to −17) .02
Serology cases were classified as having no record of active follow-up by the Public Health Unit if their notification record had missing data in the fields requesting information on hospitali-
zation or death. Both are data fields that cannot be obtained through the routine laboratory notification. Abbreviations: CI, confidence interval; OR, odds ratio; Ref, reference.
aMatched on recruitment date, age, and sex.
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